Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.43 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.43 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29453741 | 1.00 | EGFR (0.50) | EGFRNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL29256626 | 0.88 | SMN1; SMN2 (0.43) | EGFRNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL424747 | 0.83 | TUBB4A (0.54) | NPC1RAB9ASMN1; SMN2MAPTNFKB1 | |
| SCHEMBL29450481 | 0.83 | TUBB4A (0.54) | NPC1RAB9ASMN1; SMN2MAPTNFKB1 | |
| SCHEMBL3583155 | 0.82 | TSHR (0.52) | EGFRMAPTTSHRKDM4ECA12 | |
| SCHEMBL24818230 | 0.81 | LMNA (0.48) | NPC1RAB9ASMN1; SMN2MAPTNFKB1 | |
| SCHEMBL1615811 | 0.81 | NPC1 (0.46) | NPC1RAB9ASMN1; SMN2MAPTNFKB1 | |
| SCHEMBL12500156 | 0.81 | NPC1 (0.57) | NPC1RAB9ASMN1; SMN2MAPTNFKB1 | |
| SCHEMBL23345398 | 0.81 | EGFR (0.43) | EGFRSMN1; SMN2MAPTLMNA | |
| SCHEMBL28802438 | 0.81 | EGFR (0.43) | EGFRNPC1RAB9ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 287 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023122754-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING GB13, GB22 AND HIMGALINE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-06-29 | — | — | WO | claimed |
| CN-101812016-B | Method for preparing 6-methylnicotinic acid etoricoxib intermediate and ester thereof | ZHEJIANG HISOAR PHARMACEUTICAL CO LTD | 2013-01-16 | — | — | CN | claimed |
| US-12540129-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-20250387379-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFLECTION THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250375432-A1 | COMPOUNDS THAT MODULATES AMPA RECEPTOR FUNCTION | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2025-12-11 | — | — | US | disclosed |
| WO-2025224249-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2025-10-30 | — | — | WO | disclosed |
| US-12441736-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-12383540-B2 | Compounds that modulates AMPA receptor function | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2025-08-12 | — | — | US | disclosed |
| US-20250154109-A1 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | LATIGO BIOTHERAPEUTICS, INC | 2025-05-15 | — | — | US | disclosed |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| WO-1992014714-A1 | SUBSTITUTED PYRIDINONES AND PYRIMIDINONES AS ANGIOTENSIN II ANTAGONISTS | FISONS PLC (GB) | 1992-09-03 | — | — | WO | disclosed |
| EP-0500297-A1 | Substituted pyridinones and pyrimidinones as angiotensin II antagonists | FISONS plc (GB) | 1992-08-26 | — | — | EP | disclosed |
| EP-0060012-B1 | 4-HALO-1,8-NAPHTHYRIDINE DERIVATIVES USEFUL AS INTERMEDIATES AND PROCESSES FOR THEIR PREPARATION | AMERICAN HOME PRODUCTS CORPORATION (US) | 1984-08-29 | — | — | EP | disclosed |
| US-4350817-A | 4-Cl, Br or I-3-Carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1982-09-21 | — | — | US | disclosed |
| EP-0060012-A1 | 4-Halo-1,8-naphthyridine derivatives useful as intermediates and processes for their preparation | AMERICAN HOME PRODUCTS CORPORATION (US) | 1982-09-15 | — | — | EP | disclosed |
| US-4324893-A | 4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1982-04-13 | — | — | US | disclosed |
| EP-0018735-A1 | 1,8-Naphthyridine derivatives, their preparation, pharmaceutical compositions containing them | AMERICAN HOME PRODUCTS CORPORATION (US) | 1980-11-12 | — | — | EP | disclosed |
| WO-1980002287-A1 | 1,8-NAPHTHYRIDINE DERIVATIVES | AMERICAN HOME PROD (US) | 1980-10-30 | — | — | WO | disclosed |
| US-4215123-A | Antisecretory 4-oxy-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1980-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154109-A1 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | SCN8A, TRPV1, SCNN1A | EGFR 3946/4885NPC1 289/4885RAB9A 769/4885 |
| US-20250375432-A1 | COMPOUNDS THAT MODULATES AMPA RECEPTOR FUNCTION | GRIN1, GRM1, GRIN2A | EGFR 941/4885NPC1 3139/4885RAB9A 3311/4885 |
| US-12441736-B2 | KIF18A inhibitors | KIF18A, KIF18B, KIF15 | EGFR 1508/4885NPC1 917/4885RAB9A 225/4885 |
| US-12383540-B2 | Compounds that modulates AMPA receptor function | GRIN1, GRM1, GRIN2A | EGFR 960/4885NPC1 2905/4885RAB9A 3171/4885 |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | EGFR 2075/4885NPC1 224/4885RAB9A 1384/4885 |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ACE, ACE2, SPCS3 | EGFR 4140/4885NPC1 399/4885RAB9A 384/4885 |
| US-12540129-B2 | KIF18A inhibitors | KIF18A, KIFC1, KIF2C | EGFR 297/4885NPC1 218/4885RAB9A 183/4885 |
| US-20250387379-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | SUB1, AHR, NCOA3 | EGFR 32/4885NPC1 1222/4885RAB9A 2234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.